A5009478113- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Radiomics and Machine Learning in Medical Imaging
- Cardiac Imaging and Diagnostics
- Urologic and reproductive health conditions
- Brain Metastases and Treatment
- Vasculitis and related conditions
- Advanced Radiotherapy Techniques
- Neuroendocrine Tumor Research Advances
- Melanoma and MAPK Pathways
- Advanced MRI Techniques and Applications
- Cancer, Lipids, and Metabolism
- Sarcoidosis and Beryllium Toxicity Research
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Radiation Dose and Imaging
- Advanced X-ray and CT Imaging
- Systemic Sclerosis and Related Diseases
- Pituitary Gland Disorders and Treatments
- Peptidase Inhibition and Analysis
- Meningioma and schwannoma management
Royal North Shore Hospital
2016-2025
Melanoma Institute Australia
2021-2025
The University of Sydney
2005-2025
Chris O’Brien Lifehouse
2024
Mater Health Services
2023
Monash University
2023
University of California, San Francisco
2023
Concord Repatriation General Hospital
2017
Royal Prince Alfred Hospital
2017
St Vincent's Hospital Sydney
2016
<sup>68</sup>Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether affects management intent primary or recurrent <b>Methods:</b> Before undertaking PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well their proposed plan. A separate follow-up was after the scan results were...
Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours.Most reports documented the sensitivity specificity of each radiopharmaceutical independently, even suggested superiority one over other for different grades disease.Aim: The aim this work was develop a grading scheme that describes joint results in staging subjects with tumours single combined parameter.The has developed is referred as NETPET grade.Methods: This...
Objective Positron emission tomography/computed tomography ( PET / CT ) has not been well studied as a first‐line test for giant cell arteritis GCA ), due, in part, to historical limitations visualizing the cranial arteries. The Giant Cell Arteritis and Scan GAPS study was therefore carried out assess accuracy of newer generation head, neck, chest determining diagnosis . Methods In cohort, 64 patients with newly suspected underwent time‐of‐flight (1‐mm slice thickness from vertex diaphragm)...
Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma. changes early during targeted suggest the mechanisms of drug class could work synergistically. In non-comparative, randomized, phase 2 NeoTrio trial, we investigated whether boost proportion patients achieving long-term recurrence-free with neoadjuvant immunotherapy resectable stage III BRAF
The Prostate Imaging Reporting and Data System (PI-RADS) score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. PRIMARY (prostate-specific membrane antigen [PSMA]-positron emission tomography [PET]/CT) also has high diagnostic accuracy csPCa. This study aimed to develop an easily calculated combined (P) csPCa detection (International Society Urological Pathology [ISUP] ≥2) incorporating separately read PI-RADS scores, with external validation.
68Ga-prostate-specific membrane antigen (PSMA) PET/CT imaging is a relatively new technique used to evaluate the extent of disease in prostate carcinoma. Various other neoplasms may also express PSMA and show uptake on scan. We report case 62-year-old man who had scan for restaging A PSMA-avid thyroid lesion was identified, subsequent tissue sampling confirmed diagnosis follicular adenoma. It important be aware this possibility avoid misinterpretation. Tissue biopsy lesions should considered...
68Ga prostate-specific membrane antigen (PSMA) PET/CT is a new imaging technique that significantly more sensitive to prostate cancer lesions than other conventional modalities. Various benign and malignant neoplasms may also express PSMA show uptake on scan. We report case of 66-year-old man who had scan for restaging carcinoma. A PSMA-avid left femoral lymph node was identified. Subsequent biopsy confirmed the diagnosis follicular lymphoma. It important be aware this possibility avoid...
The PRIMARY score is a 5-category scale developed to identify clinically significant intraprostate malignancy (csPCa) on <sup>68</sup>Ga-prostate-specific membrane antigen (PSMA)–11 PET/CT (<sup>68</sup>Ga-PSMA PET) using combination of anatomic site, pattern, and intensity. Developed within the trial, requires evaluation in external datasets. This study aimed assess reproducibility diagnostic accuracy cohort patients who underwent multiparametric MRI (mpMRI) <sup>68</sup>Ga-PSMA PET before...
Abstract Background Oligometastatic disease in prostate cancer (PCa) is a challenging clinical scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT aims to defer androgen deprivation and may deliver sustained biochemical failure (BF) free survival selected patients. Little long-term data currently available regarding effectiveness this approach. Methods A retrospective single institution study PSMA-PET directed without initial ADT for oligo-metachronous PCa....
Diagnosis of paragangliomas (PGL) and phaeochromocytomas (PC) can be challenging particularly if the tumour is small. Detection metastatic disease important for comprehensive management malignant PC/PGL. Somatostatin receptor imaging (SRI) agents have high sensitivity these tumours, DOTA family radiopharmaceuticals labelled with 68 Gallium.To describe utility SRI in primary assessment (ie before surgery) PC/PGL whether measures maximum standardized uptake (SUVmax) could used to distinguish...
Ga-PSMA PET/CT is a new imaging technique that highly sensitive to metastatic prostate cancer lesions compared with other conventional modalities. We report case of 77-year-old man newly diagnosed carcinoma who had PSMA scan for staging his disease. An intensely PSMA-avid right pelvic mass was identified abutting the cecum and terminal ileum. Surgical removal histopathologic examination this lesion revealed diagnosis desmoid tumor. It important be aware many tumors than may also show avid...
Abstract Introduction In the current American Joint Committee on Cancer staging system, patients with pelvic nodal metastases are considered stage IV prostate cancer. This study aims to investigate whether men prostate‐specific membrane antigen positron emission tomography (PSMA PET)‐detected node‐positive cancer at diagnosis have a better outcome compared disease identified conventional imaging. Methods is retrospective cohort comparing outcomes of and confined pelvis, staged versus PSMA...
Background Neoadjuvant immunotherapy has become the new standard of care for stage III melanoma. This study sought to describe metabolic changes seen with fludeoxyglucose-18-positron emission tomography (FDG-PET) following neoadjuvant in patients melanoma and explore associations pathological response recurrence-free survival (RFS). Methods Data from macroscopic nodal treated checkpoint inhibitor therapy were pooled five centers. All underwent baseline preoperative FDG-PET CT assessments,...
Our objective was to study the diagnostic performance of regadenoson <sup>82</sup>Rb myocardial perfusion PET imaging detect obstructive coronary artery disease (CAD). <b>Methods:</b> We studied 134 patients (mean age, 63 ± 12 y; mean body mass index, 31 9 kg/m<sup>2</sup>) without known CAD (96 with angiography and 38 low pretest likelihood CAD). Stress left ventricular ejection fraction (LVEF) minus rest LVEF defined reserve. The Duke score used estimate anatomic extent jeopardized...
Ga prostate-specific membrane antigen (PSMA) PET/CT is a relatively new and highly sensitive imaging modality used in staging metastatic prostate cancer. We report case of 65-year-old man with newly diagnosed carcinoma who had PSMA scan for his disease. A PSMA-avid right pelvic mass was identified anterior to the sacrum. Surgical removal histopathological examination this lesion revealed diagnosis schwannoma. It important be aware that schwannoma may also show avid uptake on potentially lead...
Positron emission tomography/computed tomography (PET/CT) can detect cranial and large vessel inflammation in giant cell arteritis (GCA). We aimed to determine the change significance of vascular activity at diagnosis 6 months.Newly diagnosed GCA patients underwent time-of-flight fluorine-18-fluoro-2-deoxyglucose PET/CT from vertex diaphragm within 72 hours commencing corticosteroids were followed for 12 months. A months scan was performed with inflammatory features on biopsy or CT aortitis....
Abstract Purpose The O-(2-[ 18 F]-fluoroethyl)- l -tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET for glioblastoma patient management. imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of delineation image interpretation. Methods Sites were required to...